BONUS ZERTIFIKAT - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 15:41:43 2024-06-19 EDT | ||
| 99.88 EUR | +0.39% |
|
| Current month | +6.14% | ||
| 1 month | +8.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 99.91 | +0.42% |
| 24-06-18 | 99.49 | -0.08% |
| 24-06-17 | 99.57 | -1.45% |
| 24-06-14 | 101 | +1.27% |
| 24-06-13 | 99.77 | -0.89% |
Real-time Boerse Frankfurt Warrants
Last update June 19, 2024 at 03:41 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW914A |
| ISIN | DE000SW914A5 |
| Date issued | 2024-05-08 |
| Strike | 975 kr |
| Maturity | 2025-06-20 (366 Days) |
| Parity | 10 : 1 |
| Emission price | 87.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 101.8 € |
|---|---|
| Lowest since issue | 89.43 € |
| Spread | 1.07 € |
| Spread % | 1.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984.2
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.07%
- Stock Market
- Certificates
- Certificat
